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WS8.1 The ﬁrst 1,000 CFTR genes sequenced in the Mayo Clinic
Clinical Molecular Genetics Laboratory
W.E. Highsmith1. 1Mayo Clinic, Laboratory Medicine and Pathology, Rochester,
United States
Introduction: The Mayo Clinic Molecular Genetics Laboratory has completed
whole CFTR gene analysis for 1,154 clinical samples. Here we report our ﬁndings
for a large set of samples analyzed in an academic reference laboratory setting.
Methods: All exons of the CFTR gene were sequenced using an automated,
laboratory developed ﬂuorescent Sanger sequencing workﬂow. Whole exon dele-
tion/duplication testing was done using MLPA (MRC Holland).
Results: 43% of samples were positive for the detection of at least one potentially
disease causing allele (including 5T). 140 individuals had 2 known mutations
detected, 271 were carriers of one known mutation; 57 had one mutation and
one variant of uncertain signiﬁcance (VUS), 100 had one VUS, and 17 had 2
or more VUS’s. Of the cases with 2 mutations, 25 had one copy of the 5T allele
(13 dF508/5T); and, 41 had 2 copies of ACMG mutations (16 homozygous dF508).
Homozygous results were seen for 6 additional mutations: 2954delT, G27X, I1234V,
S945L, R75X, and R117H-7T in a 30 y/o female with pancreatitis. The majority of
cases (125/140) with 2 known, disease causing mutations were seen in patients
whose samples had a reason of referral (RFR) of possible or deﬁnite CF (or
Unknown RFR) versus those with RFR’s for pancreatitis (9) or male infertility (6).
Conclusions: The high positivity rate indicates that the test is being ordered
appropriately. However, the high number of cases with 2 ACMG panel mutations
indicates that testing ﬁrst with a panel test may be more cost effective. The number
of VUS’s is higher in individuals over 21 y/o and with a reason of referral of
pancreatitis that in individuals being tested at under 21 years of age.
WS8.2 Evaluation of next generation sequencing as a diagnostic tool
for CFTR rare mutation screening
D. Beattie1, S.V. Heggarty1, C.A. Graham1. 1Belfast City Hospital, Regional
Molecular Genetics Laboratory, Belfast, United Kingdom
The laboratory offers screening for CFTR mutations using commercial kits and
Sanger sequencing. Amplicon sequencing on a Roche GS Junior Next Generation
Sequencing (NGS) platform was evaluated for its potential to replace the current
Sanger sequencing method for rare mutation screening. The GS Junior offers up to
70 000 reads per run for amplicon sequencing and read lengths around 400 bases.
Eight compound heterozygote CF affected patients were selected with 13 unique
mutations in 10 separate exons. Various mutation types were included to test the
system’s sensitivity.
Library preparation was performed using the Multiplicom CFTR MASTR kit, which
ampliﬁes all CFTR coding regions in 2 multiplex reactions, and MID barcoding
was performed using the Multiplicom 454 MID kit which also incorporates the 454
adaptor sequences for downstream processes. Libraries were picogreen quantiﬁed,
mixed and sequenced using the Roche Titanium sequencing kit.
Data was analysed on the Roche GS Amplicon Variant Analyser. A total of 28 vari-
ants were identiﬁed (>10%), 17 of which were exonic. Only the c.1329_1330ins4
mutation in exon 9 was not called by the software although visible in the sequence. A
further 8 conﬁrmed CF patients with only one identiﬁed mutation were subsequently
sequenced. Analysis of this data has to date identiﬁed 4 potentially pathogenic
changes. Conﬁrmation by Sanger sequencing will be performed. Further sequencing
of patients is planned and data analysis with the Roche package will be compared
to the Softgenetics NextGENe software package.
NGS has the capacity to transform diagnostic testing for CF with the potential to
speed up mutation detection and reduce costs.
WS8.3 Co-implication of the 5′ and 3′ regions of CFTR exon 10 in its
alternative splicing: prediction to pathology
R. Farhat1, A. El Seedy1, M.-C. Pasquet1,2, C. Adolphe3, E. Biteh4, I. Sermet-
Gaudelus5, A. Kitzis1,2, V. Ladeveze1. 1Universite´ de Poitiers, IPBC, Poitiers,
France; 2CHU de Poitiers, Poitiers, France; 3University of Poitiers, Poitiers,
France; 4Hoˆpital Purpan, Toulouse, France; 5CRCM, Hoˆopital Necker-Enfants
Malades, Paris, France
A CF patient presents a high level of sweat chloride concentrations and expressed a
severe phenotype with pancreatic insufﬁciency, chronic cough, and bronchial infec-
tion (Haemophilus inﬂuenzae and Staphylococcus aureus). Moreover, measurements
of changes in nasal potential difference in response to chloride-free isoproterenol
show an absence of functional CFTR protein. This patient carries c.3659delC and
c.[1210−12T[5]; 1392G>T] in trans.
In this work, we investigated the implications of c.1392G>T mutation (last nu-
cleotide of exon 10) and c.1210−12T[5] (5′ of exon 10) on splicing. The effect of
the c.1392G>T mutation was studied in cis with the polymorphism 11TG 5T (the
patient’s genotype) or 11TG 7T (control) since the polymorphism c.1210–24TG[m]–
12[T]n located at the 3′ end of intron 9, is known to modulate the splicing. For
this purpose, we have used the technique of hybrid minigene construction. After
transfections, the mRNAs were extracted, and after RT-PCR, the ampliﬁed products
were sequenced.
Our results show that the complex allele c.[1210–12T[5]; 1392G>T] affects the
splicing of exon 10 and induces the production of many transcripts: one missing
the exon 10 in high quantity, and two other, not yet described, inducing a frameshift.
The complex allele c.[1210–12T[7]; 1392G>T] induces two alternative splicings:
one with exon skipping and another with frameshift, both in a low quantity. Most of
mRNA has the normal length, including the c.1392G>T mutation. We demonstrate
here that the complex allele c.[1210–12T[5];1392G>T] induces CF in patient by
alternative splicing. These results enhance the crucial role of complex alleles in CF
and in our case, on RNA splicing.
WS8.4 Consequences of partial duplications of the human CFTR
gene on CF diagnosis: mutations or ectopic variations
A. El Seedy1, M.-C. Pasquet1,2, T. Bienvenu3, E. Bieth4, M.-P. Audre´zet5,
A. Kitzis1,2, V. Ladeveze1. 1Universite´ de Poitiers, IPBC, Poitiers, France; 2CHU
de Poitiers, Poitiers, France; 3Groupe Hospitalier Cochin St Vincent de Paul,
Paris, France; 4CHU de Toulouse, Poitiers, France; 5Universite´ de Bretagne
Occidentale, Brest, France
CFTR exon 10 and its ﬂanking regions are duplicated in human genome. At least
8 ectopic sequences are found in the genome. These duplicated regions present
mutations in respect to the normal CFTR exon 10 sequence.
Due to the polymorphic sequence of the 3’ intron 9 sequence, it may appear difﬁcult
to sequence exon 10 and some mutations described in this exon could, in fact, be
variation observed in an ectopic duplicated exon 10.
In a previous work (A. el Seedy et al., 2009) we described a methodology to realise
PCR only of exon 10 and not of ectopic regions. We then shown that the previously
described c.[1392+6insC; c.1392+12G>A] mutations are in fact a sequence present
in an ectopic duplicated exon 10 and not in CFTR gene.
In this work, we analysed mutations described in the CF data base as being CFTR
mutations but also found in ectopic exon 10 regions: c.1392G>T (p.Lys464Asn),
c.1338_1339delAT (p.Ile444X), c.1235delC (p.Ala412GlufsX30), and c.1247A>G
(p.Asn416Ser). We show that these mutations appear to be authentic mutations
in CFTR exon10 and not ectopic variations in analysed patients. These mutations
validate the usefulness of our new strategy in the mutation analysis of this region
of CFTR.
